Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia

The advent of novel immunotherapies, such as blinatumomab, inotuzumab, and chimeric antigen receptor (CAR) T cell therapy, has revolutionized the therapeutic landscape in the treatment of relapsed/refractory B cell acute lymphoblastic leukemia, but can be associated with specific toxicities. We revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Tania, Litzow, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971963/
https://www.ncbi.nlm.nih.gov/pubmed/32010436
http://dx.doi.org/10.1177/2040620719899897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971963/
https://www.ncbi.nlm.nih.gov/pubmed/32010436
http://dx.doi.org/10.1177/2040620719899897

Ejemplares similares